In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | -100% |
2016 | -$0.09 M | -172.92% |
2015 | $0.11 M | -59.77% |
2014 | $0.29 M | -75.86% |
2013 | $1.2 M | -12.04% |
2012 | $1.36 M | 12.07% |
2011 | $1.22 M | -14.46% |
2010 | $1.42 M | 43.72% |
2009 | $0.99 M | 328.46% |
2008 | $0.23 M | 308.54% |
2007 | $0.05 M | -38.91% |
2006 | $0.09 M | -54.91% |
2005 | $0.2 M | 46% |
2004 | $0.14 M | -48.42% |
2003 | $0.27 M | -34.17% |
2002 | $0.41 M | -48.42% |
2001 | $0.8 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | N/A | ๐บ๐ธ USA |